NYSE:ELAN
Elanco Animal Health Inc
A global provider of veterinary pharmaceuticals and nutrition solutions for pets and livestock facing recent profitability headwinds.
Key Metrics
Investment Thesis
Bull Case
The company maintains a massive cash hoard of $545M and strong operating cash flows that could fund future acquisitions or R&D to restore profitability; Its diverse product portfolio across pets and livestock offers defensive characteristics during economic downturns; Potential for strategic divestitures or restructuring could unlock hidden value in its underperforming segments.
Bear Case
Consecutive years of net losses in 2023 and 2025, alongside a large retained earnings deficit of $2.18B, signal serious underlying profitability issues; High operating expenses relative to revenue suggest inefficient cost management or failing product lines; The heavy reliance on intangible assets ($3.41B) poses amortization risks that could further erode future earnings.
About Elanco Animal Health Inc
Elanco Animal Health Inc is a global leader in veterinary pharmaceuticals, nutrition, and wellness products serving pets, livestock, and food-producing animals. The company generates revenue primarily through its specialty animal health segment focusing on companion animal care, along with broader agricultural solutions. Key products include medications for treating diseases in dogs and cats, feed additives for livestock growth, and vaccines.
Analysis
Management Discussion
Despite a revenue increase to $4.71B in 2025, the company reported a net loss of $232M, marking a sharp reversal from 2024's profitability. Operating expenses totaling $2.82B exceeded gross profit of $2.59B, indicating margin compression likely driven by increased G&A costs or one-time charges. The cash flow from operations remains robust at $560M, suggesting core business viability despite accounting losses.
Industry Overview
The global veterinary pharmaceutical industry is growing steadily driven by increasing pet ownership and rising disposable incomes in emerging markets. Companies face intense competition from both established giants and biotech startups, requiring continuous innovation to maintain market share. Regulatory scrutiny regarding antibiotic use in livestock adds complexity but also creates opportunities for alternative health solutions.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue | $4.41B | $4.42B | $4.44B | $4.71B |
| Cost of Revenue | $1.91B | $1.93B | $2.00B | $2.12B |
| Gross Profit | $2.50B | $2.49B | $2.44B | $2.59B |
| Operating Expenses | $2.57B | $3.68B | $1.95B | $2.82B |
| Operating Income | $-72.0M | $-1.20B | $488.0M | $-224.0M |
| R&D | $321.0M | $327.0M | $344.0M | $368.0M |
| G&A | $1.26B | $1.28B | $1.31B | $1.43B |
| Stock-Based Comp | $59.0M | $46.0M | $55.0M | $68.0M |
| D&A | $682.0M | $694.0M | $662.0M | $680.0M |
| Depreciation | $89.0M | $92.0M | $95.0M | — |
| Amortization | $528.0M | $548.0M | $527.0M | $543.0M |
| Other OpEx | $984.0M | $2.07B | $290.0M | $1.02B |
| Non-Operating Income | $0 | $0 | $0 | $0 |
| Interest Expense | $241.0M | $277.0M | — | — |
| Interest Income | — | — | $31.0M | $43.0M |
| Pre-Tax Income | $-72.0M | $-1.20B | $488.0M | $-224.0M |
| Income Tax | $6.0M | $36.0M | $150.0M | $8.0M |
| Continuing Ops | $-78.0M | $-1.23B | $338.0M | $-232.0M |
| Discontinued Ops | $0 | $0 | $0 | $0 |
| Net Income | $-78.0M | $-1.23B | $338.0M | $-232.0M |
| Minority Interest | $0 | $0 | $0 | $0 |
| Net to Common | $-78.0M | $-1.23B | $338.0M | $-232.0M |
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Current Assets | $3.28B | $3.41B | $3.21B | $3.46B |
| Cash & Equivalents | $345.0M | $352.0M | $468.0M | $545.0M |
| Accounts Receivable | $797.0M | $842.0M | $805.0M | $873.0M |
| Inventory | $1.54B | $1.74B | $1.57B | $1.74B |
| Prepaid Expenses | $394.0M | $310.0M | $287.0M | $236.0M |
| Other Current Assets | $205.0M | $168.0M | $81.0M | $67.0M |
| Long-Term Assets | $12.21B | $10.96B | $9.40B | $9.90B |
| PP&E (Net) | $999.0M | $1.03B | $993.0M | — |
| Intangibles | $4.84B | $4.49B | $3.68B | $3.41B |
| Goodwill | $5.99B | $5.09B | $4.41B | $4.78B |
| Operating Leases | $141.0M | $140.0M | $122.0M | $116.0M |
| Other LT Assets | $210.0M | $175.0M | $172.0M | $1.58B |
| Total Assets | $15.49B | $14.36B | $12.61B | $13.36B |
| Current Liabilities | $1.70B | $1.24B | $1.31B | $1.60B |
| Accounts Payable | $390.0M | $270.0M | $296.0M | $368.0M |
| Current Debt | $388.0M | $38.0M | $44.0M | — |
| Current Leases | $31.0M | $32.0M | $31.0M | $38.0M |
| Deferred Revenue | $324.0M | $367.0M | $332.0M | $416.0M |
| Other Current Liab | $569.0M | $534.0M | $612.0M | $775.0M |
| Long-Term Liabilities | $6.50B | $6.90B | $5.20B | $5.21B |
| Long-Term Debt | $5.45B | $5.74B | $4.28B | — |
| LT Operating Leases | $111.0M | $110.0M | $92.0M | $86.0M |
| Other LT Liab | $941.0M | $1.05B | $834.0M | $5.13B |
| Total Liabilities | $8.20B | $8.14B | $6.52B | $6.81B |
| Shareholders' Equity | $7.29B | $6.22B | $6.10B | $6.55B |
| Paid-In Capital | $8.74B | $8.78B | $8.82B | $8.87B |
| Retained Earnings | $-1.06B | $-2.29B | $-1.95B | $-2.18B |
| AOCI | $-392.0M | $-266.0M | $-771.0M | $-141.0M |
| Total L&E | $15.49B | $14.36B | $12.61B | $13.36B |
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Net Income (CFO) | $-78.0M | $-1.23B | $338.0M | $-232.0M |
| Non-Cash Adjustments | $264.0M | $1.39B | $188.0M | $597.0M |
| Working Capital Changes | $266.0M | $112.0M | $15.0M | $195.0M |
| Cash from Operations | $452.0M | $271.0M | $541.0M | $560.0M |
| Capital Expenditures | $137.0M | $140.0M | $147.0M | $276.0M |
| Cash from Investing | $-179.0M | $-169.0M | $1.16B | $-279.0M |
| Cash from Financing | $-549.0M | $-83.0M | $-1.49B | $-275.0M |
| FX Effect | $-17.0M | $-12.0M | $-91.0M | $71.0M |
| Net Change in Cash | $-293.0M | $7.0M | $116.0M | $77.0M |
| Beginning Cash | $638.0M | $345.0M | $352.0M | $468.0M |
| Ending Cash | $345.0M | $352.0M | $468.0M | $545.0M |
Frequently Asked Questions
How does Elanco Animal Health Inc make money?
Specialty Animal Health focuses on companion animals with patented medicines and diagnostics; Veterinary Nutrition provides feed additives for livestock and poultry; Veterinary Healthcare offers broad-spectrum animal health products for food-producing animals.
What are the main risks for ELAN?
Significant recent net losses impacting retained earnings and shareholder value; Heavy reliance on patent expirations affecting long-term growth trajectory; Regulatory changes in key markets like the US and EU could disrupt product approvals and pricing;
What is ELAN's competitive advantage?
Extensive portfolio of patented veterinary drugs providing revenue stability and pricing power; Strong global distribution network ensuring market penetration across diverse geographies; High barriers to entry due to regulatory requirements and R&D intensity in animal health.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.